Top

Published in:

Open Access 01-12-2011 | Review

Spinal muscular atrophy

Authors: Adele D'Amico, Eugenio Mercuri, Francesco D Tiziano, Enrico Bertini

Published in: Orphanet Journal of Rare Diseases | Issue 1/2011

Abstract

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by degeneration of alpha motor neurons in the spinal cord, resulting in progressive proximal muscle weakness and paralysis. Estimated incidence is 1 in 6,000 to 1 in 10,000 live births and carrier frequency of 1/40-1/60. This disease is characterized by generalized muscle weakness and atrophy predominating in proximal limb muscles, and phenotype is classified into four grades of severity (SMA I, SMAII, SMAIII, SMA IV) based on age of onset and motor function achieved. This disease is caused by homozygous mutations of the survival motor neuron 1 (SMN1) gene, and the diagnostic test demonstrates in most patients the homozygous deletion of the SMN1 gene, generally showing the absence of SMN1 exon 7. The test achieves up to 95% sensitivity and nearly 100% specificity. Differential diagnosis should be considered with other neuromuscular disorders which are not associated with increased CK manifesting as infantile hypotonia or as limb girdle weakness starting later in life.

Considering the high carrier frequency, carrier testing is requested by siblings of patients or of parents of SMA children and are aimed at gaining information that may help with reproductive planning. Individuals at risk should be tested first and, in case of testing positive, the partner should be then analyzed. It is recommended that in case of a request on carrier testing on siblings of an affected SMA infant, a detailed neurological examination should be done and consideration given doing the direct test to exclude SMA. Prenatal diagnosis should be offered to couples who have previously had a child affected with SMA (recurrence risk 25%). The role of follow-up coordination has to be managed by an expert in neuromuscular disorders and in SMA who is able to plan a multidisciplinary intervention that includes pulmonary, gastroenterology/nutrition, and orthopedic care. Prognosis depends on the phenotypic severity going from high mortality within the first year for SMA type 1 to no mortality for the chronic and later onset forms.

Available only for authorised users

Werdnig G: Zwei frühinfantile hereditäre Fälle von progressive Muskelatrophie unter dem Bilde der Dystrophie, aber auf neurotischer Grundlage [Two early infantile hereditary cases of progressive muscular atrophy simulating dystrophy, but on a neural basis; in German]. Arch Psychiatr Nervenkr. 1891, 22: 437-480. 10.1007/BF01776636.CrossRef

Hoffmann J: U" ber chronische spinale Muskelatrophie im Kindesalter, auf familiärer Basis [On chronic spinal muscular atrophy in childhood, with a familial basis; in German]. Dtsch Z Nervenheilkd. 1893, 3: 427-470. 10.1007/BF01668496.CrossRef

Brzustowicz LM, Lehner T, Castilla LH, Penchaszadeh GK, Wilhelmsen KC, Daniels R, Davies KE, Leppert M, Ziter F, Wood D, Dubowitz V, Zerres K, Hausmanowa-Petrusewicz I, Ott J, Munsat TL, Gilliam TC: Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3. Nature. 1990, 344: 540-41. 10.1038/344540a0.CrossRefPubMed

Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M, Le Paslier D, Frézal J, Cohen D, Weissenbach J, Munnich A, Melki J: Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995, 80: 155-65. 10.1016/0092-8674(95)90460-3.CrossRefPubMed

Ogino S, Leonard DG, Rennert H, Ewens WJ, Wilson RB: Genetic risk assessment in carrier testing for spinal muscular atrophy. Am J Med Genet. 2002, 110: 301-07. 10.1002/ajmg.10425.CrossRefPubMed

Prior TW, Snyder PJ, Rink BD, Pearl DK, Pyatt RE, Mihal DC, Conlan T, Schmalz B, Montgomery L, Ziegler K, Noonan C, Hashimoto S, Garner S: Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet A. 2010, 152A: 1605-1607. 10.1002/ajmg.a.33519.CrossRef

Munstat TL, Davies KE: International SMA consortium meeting. Neuromuscul Disord. 1992, 2: 423-428. 10.1016/S0960-8966(06)80015-5.CrossRef

MacLeod MJ, Taylor JE, Lunt PW, Mathew CG, Robb SA: Prenatal onset spinal muscular atrophy. Eur J Paediatr Neurol. 1999, 3: 65-72.CrossRefPubMed

Dubowitz V: Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. Eur J Paediatr Neurol. 1999, 3: 49-51.CrossRefPubMed

10.

Felderhoff-Mueser U, Grohmann K, Harder A, Stadelmann C, Zerres K, Bührer C, Obladen M: Severe spinal muscular atrophy variant associated with congenital bone fractures. J Child Neurol. 2002, 17: 718-721. 10.1177/088307380201700915.CrossRefPubMed

11.

Kelly TE, Amoroso K, Ferre M, Blanco J, Allinson P, Prior TW: Spinal muscular atrophy variant with congenital fractures. Am J Med Genet. 1999, 87: 65-68. 10.1002/(SICI)1096-8628(19991105)87:1<65::AID-AJMG13>3.0.CO;2-5.CrossRefPubMed

12.

Bertini E, Burghes A, Bushby K, Estournet-Mathiaud B, Finkel RS, Hughes RA, Iannaccone ST, Melki J, Mercuri E, Muntoni F, Voit T, Reitter B, Swoboda KJ, Tiziano D, Tizzano E, Topaloglu H, Wirth B, Zerres K: 134th ENMC International Workshop: Outcome Measures and Treatment of Spinal Muscular Atrophy, 11-13 February 2005, Naarden, The Netherlands. Neuromuscular Disorders. 2005, 15: 802-816. 10.1016/j.nmd.2005.07.005.CrossRefPubMed

13.

Rudnik-Schöneborn S, Heller R, Berg C, Betzler C, Grimm T, Eggermann T, Eggermann K, Wirth R, Wirth B, Zerres K: Congenital heart disease is a feature of severe infantile spinal muscular atrophy. J Med Genet. 2008, 45: 635-8. 10.1136/jmg.2008.057950.CrossRefPubMed

14.

Shababi M, Habibi J, Yang HT, Vale SM, Sewell WA, Lorson CL: Cardiac defects contribute to the pathology of spinal muscular atrophy models. Hum Mol Genet. 2010, 19: 4059-4071. 10.1093/hmg/ddq329.CrossRefPubMed

15.

Messina S, Pane M, De Rose P, Vasta I, Sorleti D, Aloysius A, Sciarra F, Mangiola F, Kinali M, Bertini E, Mercuri E: Feeding problems and malnutrition in spinal muscular atrophy type II. Neuromuscul Disord. 2008, 18: 389-93. 10.1016/j.nmd.2008.02.008.CrossRefPubMed

16.

Kinali M, Banks LM, Mercuri E, Manzur AY, Muntoni F: Bone mineral density in a paediatric spinal muscular atrophy population. Neuropediatrics. 2004, 35: 325-8. 10.1055/s-2004-830366.CrossRefPubMed

17.

Khatri IA, Chaudhry US, Seikaly MG, Browne RH, Iannaccone ST: Low bone mineral density in spinal muscular atrophy. J Clin Neuromuscul Dis. 2008, 10: 11-7. 10.1097/CND.0b013e318183e0fa.CrossRefPubMed

18.

Shanmugarajan S, Tsuruga E, Swoboda KJ, Maria BL, Ries WL, Reddy SV: Bone loss in survival motor neuron (Smn(-/-) SMN2) genetic mouse model of spinal muscular atrophy. J Pathol. 2009, 219: 52-60. 10.1002/path.2566.PubMedCentralCrossRefPubMed

19.

Zerres K, Rudnik-Schöneborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I: A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci. 1997, 146: 67-72. 10.1016/S0022-510X(96)00284-5.CrossRefPubMed

20.

Vitte J, Fassier C, Tiziano FD, Dalard C, Soave S, Roblot N, Brahe C, Saugier-Veber P, Bonnefont JP, Melki J: Refined characterization of the expression and stability of the SMN gene products. Am J Pathol. 2007, 171: 1269-80. 10.2353/ajpath.2007.070399.PubMedCentralCrossRefPubMed

21.

Wirth B: An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mut. 2000, 15: 228-237. 10.1002/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9.CrossRefPubMed

22.

Gavrilov DK, Shi X, Das K, Gilliam TC, Wang CH: Differential SMN2 expression associated with SMA severity. Nat Genet. 1998, 20: 230-31. 10.1038/3030.CrossRefPubMed

23.

Feldkötter M, Schwarzer V, Wirth R, Wienker TF, Wirth B: Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002, 70: 358-68. 10.1086/338627.PubMedCentralCrossRefPubMed

24.

Rudnik-Schöneborn S, Berg C, Zerres K, Betzler C, Grimm T, Eggermann T, Eggermann K, Wirth R, Wirth B, Heller R: Genotype-phenotype studies in infantile spinal muscular atrophy (SMA) type I in Germany: implications for clinical trials and genetic counselling. Clin Genet. 2009, 76: 168-178. 10.1111/j.1399-0004.2009.01200.x.CrossRefPubMed

25.

Coovert DD, Le TT, McAndrew PE, Strasswimmer J, Crawford TO, Mendell JR, Coulson SE, Androphy EJ, Prior TW, Burghes AH: The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet. 1997, 6: 1205-1214. 10.1093/hmg/6.8.1205.CrossRefPubMed

26.

Liu Q, Dreyfuss G: A novel nuclear structure containing the survival of motor neurons protein. EMBO J. 1996, 15: 3555-3565.PubMedCentralPubMed

27.

Schmid A, DiDonato CJ: Animal models of spinal muscular atrophy. J Child Neurol. 2007, 22: 1004-1012. 10.1177/0883073807305667. Review.CrossRefPubMed

28.

Monani UR, Pastore MT, Gavrilina TO, Jablonka S, Le TT, Andreassi C, DiCocco JM, Lorson C, Androphy EJ, Sendtner M, Podell M, Burghes AH: A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy. J Cell Biol. 2003, 160: 41-52. 10.1083/jcb.200208079.PubMedCentralCrossRefPubMed

29.

Le TT, Pham LT, Butchbach ME, Zhang HL, Monani UR, Coovert DD, Gavrilina TO, Xing L, Bassell GJ, Burghes AH: SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet. 2005, 14: 845-857. 10.1093/hmg/ddi078.CrossRefPubMed

30.

Carvalho T, Almeida F, Calapez A, Lafarga M, Berciano MT, Carmo-Fonseca M: The spinal muscular atrophy disease gene product, SMN: A link between snRNP biogenesis and the Cajal (coiled) body. J Cell Biol. 1999, 147: 715-2836,39. 10.1083/jcb.147.4.715.PubMedCentralCrossRefPubMed

31.

Gabanella F, Butchbach ME, Saieva L, Carissimi C, Burghes AH, Pellizzoni L: Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs. PLoS One. 2007, 2: e921. 10.1371/journal.pone.0000921.PubMedCentralCrossRefPubMed

32.

Fan L, Simard LR: Survival motor neuron (SMN) protein: role in neurite outgrowth and neuromuscular maturation during neuronal differentiation and development. Hum Mol Genet. 2002, 11: 1605-14. 10.1093/hmg/11.14.1605.CrossRefPubMed

33.

Zhang H, Xing L, Rossoll W, Wichterle H, Singer RH, Bassell GJ: Multiprotein complexes of the survival of motor neuron protein SMN with Gemins traffic to neuronal processes and growth cones of motor neurons. J Neurosci. 2006, 26: 8622-8632. 10.1523/JNEUROSCI.3967-05.2006.CrossRefPubMed

34.

Lunn MR, Wang CH: Spinal muscular atrophy. Lancet. 2008, 371: 2120-2133. 10.1016/S0140-6736(08)60921-6. Review.CrossRefPubMed

35.

Rossoll W, Jablonka S, Andreassi C, Kröning AK, Karle K, Monani UR, Sendtner M: Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motorneurons. J Cell Biol. 2003, 163: 801-812. 10.1083/jcb.200304128.PubMedCentralCrossRefPubMed

36.

Zhang HL, Pan F, Hong D, Shenoy SM, Singer RH, Bassell GJ: Active transport of the survival motor neuron protein and the role of exon-7 in cytoplasmic localization. J Neurosci. 2003, 23: 6627-6637.PubMed

37.

McWhorter ML, Monani UR, Burghes AH, Beattie CE: Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. J Cell Biol. 2003, 162: 919-931. 10.1083/jcb.200303168.PubMedCentralCrossRefPubMed

38.

Lambrechts A, Braun A, Jonckheere V, Aszodi A, Lanier LM, Robbens J, Van Colen I, Vandekerckhove J, Fässler R, Ampe C: Profilin II is alternatively spliced, resulting in profilin isoforms that are differentially expressed and have distinct biochemical properties. Mol Cell Biol. 2000, 20: 8209-8219. 10.1128/MCB.20.21.8209-8219.2000.PubMedCentralCrossRefPubMed

39.

Setola V, Terao M, Locatelli D, Bassanini S, Garattini E, Battaglia G: Axonal-SMN (a-SMN), a protein isoform of the survival motor neuron gene, is specifically involved in axonogenesis. Proc Natl Acad Sci USA. 2007, 104: 1959-1964. 10.1073/pnas.0610660104.PubMedCentralCrossRefPubMed

40.

Simic G: Pathogenesis of proximal autosomal recessive spinal muscular atrophy. Acta Neuropathol. 2008, 116: 223-234. 10.1007/s00401-008-0411-1.CrossRefPubMed

41.

Sharma A, Lambrechts A, Hao le T, Le TT, Sewry CA, Ampe C, Burghes AH, Morris GE: A role for complexes of survival of motor neurons (SMN) protein with gemins and profilin in neurite-like cytoplasmic extensions of cultured nerve cells. Exp Cell Res. 2005, 309: 185-97. 10.1016/j.yexcr.2005.05.014.CrossRefPubMed

42.

Mentis GZ, Blivis D, Liu W, Drobac E, Crowder ME, Kong L, Alvarez FJ, Sumner CJ, O'Donovan MJ: Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy. Neuron. 2011, 69: 453-467. 10.1016/j.neuron.2010.12.032.PubMedCentralCrossRefPubMed

43.

Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, Aloysius A, Morrison L, Main M, Crawford TO, Trela A: Participants of the International Conference on SMA Standard of Care. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007, 22: 1027-1049. 10.1177/0883073807305788.CrossRefPubMed

44.

Arkblad EL, Darin N, Berg K, Kimber E, Brandberg G, Lindberg C, Holmberg E, Tulinius M, Nordling M: Multiplex ligation-dependent probe amplification improbe diagnostics in spinal muscular atrophy. Neuromuscul Disord. 2006, 16: 830-838. 10.1016/j.nmd.2006.08.011.CrossRefPubMed

45.

Cuscó I, López E, Soler-Botija C, Jesús Barceló M, Baiget M, Tizzano EF: A genetic and phenotypic analysis in Spanish spinal muscular atrophy patients with c.399_402del AGAG, the most frequently found subtle mutation in the SMN1 gene. Hum Mutat. 2003, 22: 136-43. 10.1002/humu.10245.CrossRefPubMed

46.

Brahe C, Vitali T, Tiziano FD, Angelozzi C, Pinto AM, Borgo F, Moscato U, Bertini E, Mercuri E, Neri G: Phenylbutyrate increases SMN gene expression in spinal muscular atrophy Patients. Eur J Hum Genet. 2005, 13: 356-259.CrossRef

47.

Weihl CC, Connolly AM, Pestronk A: Valproate may improve strength and function in patients with type III/IV spinal muscular atrophy. Neurology. 2006, 67: 500-501. 10.1212/01.wnl.0000231139.26253.d0.CrossRefPubMed

48.

Brichita L, Holker I, Huang K, Klockgether T, Wirth B: In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann Neurol. 2006, 59: 970-9. 10.1002/ana.20836.CrossRef

49.

Tsai LK, Yang CC, Hwu WL, Li H: Valproic acid treatment in six patients with spinal muscular atrophy. Eur J N Neurol. 2007, 14: e8-e9.CrossRef

50.

Swoboda KJ, Scott CB, Reyna SP, Prior TW, LaSalle B, Sorenson SL, Wood J, Acsadi G, Crawford TO, Kissel JT, Krosschell KJ, D'Anjou G, Bromberg MB, Schroth MK, Chan GM, Elsheikh B, Simard LR: Phase II open label study of valproic acid in spinal muscular atrophy. 2009, PLoS ONE 4: e5268.

51.

Swoboda KJ, Prior TW, Scott CB, McNaught TP, Wride MC, Reyna SP, Bromberg MB: Natural history of denervation in SMA: Relation to age, SMN2 copy number, and function. Ann Neurol. 2005, 57: 704-712. 10.1002/ana.20473.PubMedCentralCrossRefPubMed

52.

Mellies U, Dohna-Schwake C, Stehling F, Voit T: Sleep disordered breathing in spinal muscular atrophy. Neuromuscul Disord. 2004, 14: 797-803. 10.1016/j.nmd.2004.09.004.CrossRefPubMed

53.

Mellies U, Ragette R, Dohna Schwake C, Boehm H, Voit T, Teschler H: Long-term noninvasive ventilation in children and adolescents with neuromuscular disorders. Eur Respir J. 2003, 22: 631-636. 10.1183/09031936.03.00044303a.CrossRefPubMed

54.

Ragette R, Mellies U, Schwake C, Voit T, Teschler H: Patterns and predictors of sleep disordered breathing in primary myopathies. Thorax. 2002, 57: 724-728. 10.1136/thorax.57.8.724.PubMedCentralCrossRefPubMed

55.

Akbarnia BA, Marks DS, Boachie-Adjei O, Thompson AG, Asher MA: Dual growing rod technique for the treatment of progressive early-onset scoliosis: a multicenter study. Spine. 2005, 30 (17 Suppl): S46-57.CrossRefPubMed

56.

Hell AK, Campbell RM, Hefti F: The vertical expandable prosthetic titanium rib implant for the treatment of thoracic insufficiency syndrome associated with congenital and neuromuscular scoliosis in young children. J Pediatr Orthop B. 2005, 14: 287-293. 10.1097/01202412-200507000-00011.CrossRefPubMed

57.

Lorson CL, Rindt H, Shababi M: Spinal muscular atrophy: mechanisms and therapeutic strategies. Hum Mol Genet. 2010, 19: R111-118. 10.1093/hmg/ddq147.PubMedCentralCrossRefPubMed

58.

Tiziano FD, Lomastro R, Pinto AM, Messina S, D'Amico A, Fiori S, Angelozzi C, Pane M, Mercuri E, Bertini E, Neri G, Brahe C: Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. J Med Genet. 2010, 47: 856-858. 10.1136/jmg.2010.080366.CrossRefPubMed

59.

Lim SR, Hertel KJ: Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3' splice site pairing. J Biol Chem. 2001, 276: 45476-45483. 10.1074/jbc.M107632200.CrossRefPubMed

60.

Madocsai C, Lim SR, Geib T, Lam BJ, Hertel KJ: Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs. Mol Ther. 2005, 12: 1013-1022. 10.1016/j.ymthe.2005.08.022.CrossRefPubMed

61.

Geib T, Hertel KJ: Restoration of full-length SMN promoted by adenoviral vectors expressing RNA antisense oligonucleotides embedded in U7 snRNAs. PLoS One. 2009, 4: e8204. 10.1371/journal.pone.0008204.PubMedCentralCrossRefPubMed

62.

Jarecki J, Chen X, Bernardino A, Coovert DD, Whitney M, Burghes A, Stack J, Pollok BA: Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum Mol Genet. 2005, 14: 2003-18. 10.1093/hmg/ddi205.CrossRefPubMed

63.

Butchbach ME, Singh J, Thorsteinsdóttir M, Saieva L, Slominski E, Thurmond J, Andrésson T, Zhang J, Edwards JD, Simard LR, Pellizzoni L, Jarecki J, Burghes AH, Gurney ME: Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Hum Mol Genet. 2010, 19: 454-467. 10.1093/hmg/ddp510.PubMedCentralCrossRefPubMed

64.

Mattis VB, Rai R, Wang J, Chang CW, Coady T, Lorson CL: Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts. Hum Genet. 2006, 120: 589-601. 10.1007/s00439-006-0245-7.CrossRefPubMed

65.

Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J, Elfring GL, Northcutt VJ, Miller LL, Kerem B, Wilschanski M: Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet. 2008, 372: 719-727. 10.1016/S0140-6736(08)61168-X.CrossRefPubMed

66.

Chuang DM, Leng Y, H J, Chiu CT: Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009, 32: 591-601. 10.1016/j.tins.2009.06.002.PubMedCentralCrossRefPubMed

67.

Avila AM, Burnett BG, Taye AA, Gabanella F, Knight MA, Hartenstein P, Cizman Z, Di Prospero NA, Pellizzoni L, Fischbeck KH, Sumner CJ: Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest. 2007, 117: 659-671. 10.1172/JCI29562.PubMedCentralCrossRefPubMed

68.

Narver HL, Kong L, Burnet BG, Choe DW, Bosch-Marce M, Taye AA, Eckhaus MA, Sumner CJ: Sustained improvement of spinal muscular atrophy mice treated with trichostatin a plus nutrition. Ann Neurol. 2008, 64: 465-470. 10.1002/ana.21449.CrossRefPubMed

69.

Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, Li H: Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA. 2001, 98: 9808-9813. 10.1073/pnas.171105098.PubMedCentralCrossRefPubMed

70.

Mercuri E, Bertini E, Messina S, Solari A, D'Amico A, Angelozzi C, Battini R, Berardinelli A, Boffi P, Bruno C, Cini C, Colitto F, Kinali M, Minetti C, Mongini T, Morandi L, Neri G, Orcesi S, Pane M, Pelliccioni M, Pini A, Tiziano FD, Villanova M, Vita G, Brahe C: Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology. 2007, 68: 51-55. 10.1212/01.wnl.0000249142.82285.d6.CrossRefPubMed

71.

Garbes L, Riessland M, Holker I, Heller R, Hauke J, Trankle C, Coras R, Blumcke I, Hahnen E, Wirth B: LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. Hum Mol Genet. 2009, 18: 3645-3658. 10.1093/hmg/ddp313.CrossRefPubMed

72.

Riessland M, Ackermann B, Forster A, Jakubik M, Hauke J, Garbes L, Fritzsche I, Mende Y, Blumcke I, Hahnen E, Wirth B: SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum Mol Genet. 2010, 19: 1492-1506. 10.1093/hmg/ddq023.CrossRefPubMed

73.

Passini MA, Cheng SH: Prospects for the gene therapy of spinal muscular atrophy. Trends Mo Med 2011. 2011, 17: 259-65.

74.

Passini MA, Bu J, Roskelley EM, Richards AM, Sardi SP, O'Riordan CR, Klinger KW, Shihabuddin LS, Cheng SH: CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest. 2010, 120: 1253-1264. 10.1172/JCI41615.PubMedCentralCrossRefPubMed

75.

Dominguez E, Marais T, Chatauret N, Benkhelifa-Ziyyat S, Duque S, Ravassard P, Carcenac R, Astord S, de Moura AP, Voit T, Barkats M: Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet. 2011, 20: 681-693. 10.1093/hmg/ddq514.CrossRefPubMed

76.

Foust KD, Wang X, McGovern VL, Braun L, Bevan AK, Haidet AM, Le TT, Morales PR, Rich MM, Burghes AH, Kaspar BK: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol. 2010, 28: 271-274. 10.1038/nbt.1610.PubMedCentralCrossRefPubMed

77.

Passini MA, Bu J, Richards AM, Kinnecom C, Sardi SP, Stanek LM, Hua Y, Rigo F, Matson J, Hung G, Kaye EM, Shihabuddin LS, Krainer AR, Bennett CF, Cheng SH: Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med. 2011, 3: 72ra18. 10.1126/scitranslmed.3001777.PubMedCentralCrossRefPubMed

78.

Harper JM, Krishnan C, Darman JS, Deshpande DM, Peck S, Shats I, Backovic S, Rothstein JD, Kerr DA: Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motoneuron- injured adult rats. Proc Natl Acad Sci USA. 2004, 101: 7123-7128. 10.1073/pnas.0401103101.PubMedCentralCrossRefPubMed

79.

Deshpande DM, Kim YS, Martinez T, Carmen J, Dike S, Shats I, Rubin LL, Drummond J, Krishnan C, Hoke A, Maragakis N, Shefner J, Rothstein JD, Kerr DA: Recovery from paralysis in adult rats using embryonic stem cells. Ann Neurol. 2006, 60: 32-44. 10.1002/ana.20901.CrossRefPubMed

80.

Corti S, Nizzardo M, Nardini M, Donadoni C, Salani S, Ronchi D, Simone C, Falcone M, Papadimitriou D, Locatelli F, Mezzina N, Gianni F, Bresolin N, Comi GP: Embryonic stem cell-derived neural stem cells improve spinal muscular atrophy phenotype in mice. Brain. 2010, 133: 465-481. 10.1093/brain/awp318.CrossRefPubMed

81.

Corti S, Nizzardo M, Nardini M, Donadoni C, Salani S, Del Bo R, Papadimitriou D, Locatelli F, Mezzina N, Gianni F, Bresolin N, Comi GP: Motorneuron transplantation rescues the phenotype of SMARD1 (spinal muscular atrophy with respiratory distress type 1). J Neurosci. 2009, 29: 11761-11771. 10.1523/JNEUROSCI.2734-09.2009.CrossRefPubMed

82.

Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, Croft GF, Saphier G, Leibel R, Goland R, Wichterle H, Henderson CE, Eggan K: Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008, 321: 1218-1221. 10.1126/science.1158799.CrossRefPubMed

Title: Spinal muscular atrophy
Authors: Adele D'Amico
Eugenio Mercuri
Francesco D Tiziano
Enrico Bertini
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Orphanet Journal of Rare Diseases / Issue 1/2011
Electronic ISSN: 1750-1172
DOI: https://doi.org/10.1186/1750-1172-6-71

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Spinal muscular atrophy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Population-based evaluation of a suggested anatomic and clinical classification of congenital heart defects based on the International Paediatric and Congenital Cardiac Code

Autosomal recessive cerebellar ataxia caused by mutations in the PEX2 gene

Ichthyosis follicularis, alopecia, and photophobia (IFAP) syndrome

Type 1 autoimmune pancreatitis

Biomarker analysis of Morquio syndrome: identification of disease state and drug responsive markers

Phenotypic variability of the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA): clinical, molecular and biochemical delineation